How should an allergic reaction to iron dextran infusion be managed?

Management of Allergic Reactions to Iron Dextran Infusion

Immediately stop the infusion, maintain IV access with normal saline, and classify the reaction severity to guide treatment—mild reactions require monitoring only, moderate reactions need corticosteroids and H2-antagonists, and severe reactions demand immediate intramuscular epinephrine 0.3 mg with emergency services activation 1.

Immediate Actions Upon Any Reaction

When symptoms develop during iron dextran infusion:

• Stop the infusion immediately and notify the physician
• Switch the IV line to normal saline at keep-vein-open (KVO) rate
• Perform rapid physical assessment of symptoms
• Monitor vital signs continuously (BP, pulse, respiratory rate, O2 saturation, temperature) until stable 1

Severity Classification and Treatment Algorithm

Mild Hypersensitivity Reactions

Symptoms: Pruritus, flushing, urticaria, chest tightness, back pain, or joint pain

Management:

• Monitor for ≥15 minutes
• Maintain IV normal saline at KVO
• Consider hydrocortisone 100-500 mg IV
• Consider famotidine 20 mg IV 1

Moderate Hypersensitivity Reactions

Symptoms: All mild symptoms PLUS transient cough, shortness of breath, tachycardia, or hypotension (SBP drop ≥30 mmHg from baseline or SBP ≤90 mmHg)

Management:

• All interventions for mild reactions PLUS:
• If hypotensive: recline patient flat and administer NS bolus 1000-2000 mL
• If hypoxemic: provide O2 by mask or nasal cannula
• Consider albuterol 0.083% via nebulizer 1

Severe/Life-Threatening Reactions (Anaphylaxis)

Symptoms: Sudden onset with rapid intensification, loss of consciousness, severe hypotension, angioedema of tongue/airway, OR involvement of ≥2 organ systems (cardiovascular, skin, respiratory, gastrointestinal)

Management:

• Immediately call emergency services or resuscitation team
• Administer epinephrine (1 mg/mL) 0.3 mg IM into anterolateral mid-thigh—may repeat once
• Treat as moderate HSR (corticosteroids, H2-antagonists, fluids, oxygen)
• Consider β2-agonist nebulizer 1

Critical Context: Iron Dextran-Specific Risks

Iron dextran carries the highest risk of severe reactions among all IV iron formulations, with documented anaphylaxis occurring in 36 per 10,000 exposures (0.36%) compared to other formulations 2. The FDA label explicitly warns that fatal anaphylactic reactions have occurred even after tolerated test doses 3. This distinguishes iron dextran from newer formulations like ferric carboxymaltose, which has the lowest documented adverse reaction rate at 0.24% 2.

Mechanism Distinction Matters for Management

Most reactions to IV iron represent complement activation-related pseudo-allergy (CARPA) rather than true IgE-mediated anaphylaxis 4, 5. CARPA reactions:

• Are usually self-limited and resolve without treatment
• Occur during the first minute of infusion
• Do not require prior sensitization
• Respond to slowing or stopping the infusion

True anaphylaxis is rare but life-threatening and requires immediate epinephrine 1.

Common Pitfalls to Avoid

1. Do not resume the infusion after any reaction without physician reassessment—even mild reactions can progress 1

2. Do not rely on test doses for safety—fatal reactions have occurred despite tolerated test doses 3

3. Do not confuse delayed reactions (24-48 hours post-infusion) with acute hypersensitivity—delayed arthralgia, fever, and myalgia are common with iron dextran and managed with NSAIDs, not emergency interventions 1, 3

4. Maximum daily dose is 2 mL undiluted iron dextran—exceeding this increases adverse reaction risk 3

High-Risk Patient Identification

Patients at elevated risk who warrant heightened vigilance include those with:

• Prior reaction to IV iron
• Multiple drug allergies
• Severe asthma or eczema
• Mastocytosis
• Concomitant ACE inhibitor use 3, 4

For these patients, consider alternative IV iron formulations with lower reaction rates rather than iron dextran 2.

Post-Reaction Management

After any reaction, resuscitation equipment and personnel trained in anaphylaxis management must remain immediately available throughout the observation period 3. Patients who experience reactions are significantly less likely to complete their iron replacement regimen (OR 0.004 for iron dextran) 6, necessitating discussion of alternative formulations or routes.